

Company No. 474958

DALES PHARMACEUTICALS LIMITED
(Company)

DIRECTOR'S STATEMENT OF SOLVENCY
(for the purposes of section 642 of the Companies Act 2006)

It is proposed that the Company effects the following reduction of capital supported by a solvency statement pursuant to section 642 of the Companies Act 2006 (**Proposed Reduction**):

That the share capital of the Company be reduced by cancelling and extinguishing for no consideration the following shares:

No. of ordinary shares of £1 each:	Registered holder:
299,999	Veneto Limited

No. of fixed rate preference shares of £1 each:	Registered holder:
15,000	Veneto Limited

We, Anthony Gerard Griffin and Ian David Page, being all the Directors of the Company, make the following statements in relation to the Proposed Reduction for the purposes of section 642 of the Companies Act 2006:

1. we have formed the opinion, as regards the Company's situation at the date of this statement, that there is no ground on which the Company could then be found to be unable to pay (or otherwise discharge) its debts;
2. the Company will be able to pay (or otherwise discharge) its debts as they fall due during the year immediately following the date of this statement; and
3. in forming these opinions, we have each taken into account all of the Company's liabilities (including any contingent or prospective liabilities) as required by section 643(2) of the Companies Act 2006.

Made and signed on 12 May 2021 by each of the above named Directors of the Company:



ANTHONY GERARD GRIFFIN



IAN DAVID PAGE

FRIDAY



AA4GCUZ7

A25

14/05/2021

#211

COMPANIES HOUSE